Trend Chart On Innovative Bioindustries - July 2020, 29th FEATURE STORY GSK and CureVac announce strategic mRNA technology collaboration GSK and CureVac announced on July 20th the signing of a strategic collaboration agreement for the research, development, manufacturing and commercialisation of up to five mRNA-based vaccines and monoclonal antibodies targeting…..
Trend Chart On Innovative Bioindustries - June 2020, 2nd FEATURE STORY ● Novartis snags EU nod for SMA gene therapy After a manufacturing-related delay, Novartis has won conditional approval in the EU for Zolgensma®, the one-time gene therapy to treat patients with a clinical diagnosis of SMA type 1 and…..
Covid-19 et remdesivir : Lettre ouverte de Daniel O’Day, CEO de Gilead Sciences 4 avril 2020. Au cours de la semaine dernière, Gilead a travaillé, en collaboration avec les autorités de santé, à la mise en place de programmes d'accès complémentaires pour mettre à disposition des patients, notre médicament expérimental…..
Remdesivir and Covid-19: an update from Daniel O'Day, chairman and CEO of Gilead April 04, 2020. Over the course of the past week, Gilead has been working in consultation with regulatory authorities to establish additional expanded access programs for remdesivir, our investigational medicine for COVID-19. The programs enable hospitals or…..